Strategic Report AstraZeneca at a glance AstraZeneca is a global, science-led biopharmaceutical business with an on-market portfolio in our chosen therapy areas.
Respiratory, Inflammation Cardiovascular Oncology Infection, Neuroscience and Autoimmunity and Metabolic diseases and Gastrointestinal $4,987m $9,489m $2,825m $6,340m Product Sales Product Sales Product Sales Product Sales 2014: $5,063m 2014: $9,802m 2014: $3,027m 2014: $8,203m 2013: $4,677m 2013: $8,830m 2013: $3,193m 2013: $9,011m Highlights Respiratory sales up by 7%, Brilinta Brilique sales up by 44%, Oncology sales up by 7% Sales of Nexium declined by 26%, including 25% in Emerging Markets, including 64% in the US including 52% in the US following New Oncology included for the first before completion of the acquisition loss of exclusivity Diabetes sales up by 26%, including time comprising Lynparza, Iressa of Takedas respiratory business 76% in Emerging Markets US and Tagrisso Sales of Seroquel XR fell by 12% Sales of Symbicort down by 3% and Synagis fell by 26% Sales of Crestor fell by 3% reflecting Lynparza launched in 15 markets competition from generic statins and and sales of $94 million pricing pressure Sales and Marketing from page 48, Financial Review from page 62 and Geographical Review from page 227 We have distinctive R&D capabilities, a growing late-stage pipeline Main therapy areas Opportunity-driven Respiratory, Cardiovascular Oncology Infection, Neuroscience Inflammation and and Metabolic and Gastrointestinal Autoimmunity diseases Small molecules Biologics Immunotherapies Protein engineering Devices Personalised healthcare and translational science capabilities NMEs in Phase III, pivotal Phase II or under regulatory review 15 15 2015 13 2014 11 2013 Therapy Area Review from page 24 and Research and Development from page 42 6 2012 2 AstraZeneca Annual Report and Form 20-F Information 2015 Strategic Report and a strong global commercial presence, with strength in Emerging Markets.
North America Europe International and Japan $10,007m $5,323m $8,311m Product Sales Product Sales Product Sales 2014: $10,710m 2014: $6,638m 2014: $8,747m 2013: $10,328m 2013: $6,658m 2013: $8,725m Employees 7,600 5,900 21,900 Highlights Sales in the US declined by 6% reflecting entry Sales declined by 6% Emerging Markets revenue grew by 12% of generic Nexium products and adverse Synagis to $5,822 million, including China sales Strong growth for Diabetes medicines was guideline changes growth of 15% offset by generic competition facing Crestor and Favourable performances were delivered by Brilinta, Seroquel XR Sales in Japan grew by 4% to $2,020 million Farxiga, Bydureon and Lynparza as well as the 14% decline in Symbicort sales reflected adverse Opened facility in Russia acquired Respiratory medicines, Tudorza and Daliresp pricing movements driven by competition from Sales in Canada grew by 4% analogues in key markets Business Review from page 42 Our talented employees are committed to achieving our Purpose in a sustainable way 61,500 8,900 12,500 employees worldwide employees in R&D employees in Manufacturing and Supply Increasing our proximity to bioscience clusters and co-locating around three strategic R&D centres Cambridge, UK Gaithersburg, Maryland US Gothenburg, Sweden Employees from page 52... and our disciplined $3,443m $2.80 capital allocation enables commitment to a Net cash shareholder distributions Dividend per Ordinary Share progressive dividend.
increased to $3,443 million unchanged 2015 $3,443m 2015 $2.80 All growth rates at CER.
AstraZeneca Annual Report and Form 20-F Information 2015 3
